Skip to main content
Top
Published in: Medical Oncology 4/2013

01-12-2013 | Original Paper

Surveillance mammography use after treatment of primary breast cancer and racial disparities in survival

Authors: Z. Z. Nurgalieva, L. Franzini, R. Morgan, S. W. Vernon, C. C. Liu, X. L. Du

Published in: Medical Oncology | Issue 4/2013

Login to get access

Abstract

Racial and ethnic minority patients continue to die disproportionately from breast cancer compared with their white counterparts, even after adjusting for insurance status and income. No studies have examined whether surveillance mammography reduces racial disparities in survival among elderly breast cancer survivors following active treatment for breast cancer. This study included 28,117 cases diagnosed with primary breast cancer at age 66 years and over, identified from SEER data during 1992–2005. Kaplan–Meier methods and Cox regression models were used for survival analysis. A higher proportion of whites received surveillance mammograms during the surveillance period compared with nonwhites: 71.7 % of African-Americans, 72.5 % of Hispanics, and 69.3 % of Asians had mammograms compared with 74.9 % of whites. In propensity-score-adjusted analysis, women who had a mammogram within 2 years were less likely (hazard ratio 0.84; 95 % CI 0.78–0.82) to die from any cause compared with women who did not have any mammograms during this time period. The hazard ratio of cancer-specific mortality elevated for Hispanics compared with whites (hazard ratio 1.5; 95 % CI 0.6–3.2) and was reduced after adjusting for surveillance mammography (hazard ratio 1.4; 95 % CI 0.5–2.9). Similar pattern in the reduction in disease-specific hazard ratio was observed for blacks: After controlling for patient and tumor characteristics, hazard ratio was elevated but not significantly different from that in whites (hazard ratio 2.0; 95 % CI 0.9–3.7), and hazard ratio adjusting for surveillance mammography further reduced the point estimate (hazard ratio 1.5; 95 % CI 0.7–2.8). Asian and Pacific Islanders and Hispanics appeared to have lower risks of all-cause mortality compared with whites after controlling for patient and tumor characteristics and surveillance mammogram received. Our findings indicates that while surveillance mammograms and physician visits may play a contributory role in achieving equal outcomes for breast cancer-specific mortality for women with breast cancer, searching for other factors that might help achieve national goals to eliminate racial disparities in healthcare, and outcomes is warranted.
Literature
1.
go back to reference Mead H, Cartwright-Smith L, Jones K, et al. Racial and Ethnic Disparities in US Healthcare: A Chartbook. New York: The Commonwealth Fund; 2008. Mead H, Cartwright-Smith L, Jones K, et al. Racial and Ethnic Disparities in US Healthcare: A Chartbook. New York: The Commonwealth Fund; 2008.
2.
go back to reference Smith TJ, Davidson NE, Schapira DV, et al. American society of clinical oncology 1998 update of recommended breast cancer surveillance guidelines. J Clin Oncol. 1999;17:1080–2.PubMed Smith TJ, Davidson NE, Schapira DV, et al. American society of clinical oncology 1998 update of recommended breast cancer surveillance guidelines. J Clin Oncol. 1999;17:1080–2.PubMed
4.
go back to reference Clark A, Fong C, Romans M. Health disparities among U.S. women of color: an overview. Washington, DC: The Jacobs Institute of Women’s Health; 2002. Clark A, Fong C, Romans M. Health disparities among U.S. women of color: an overview. Washington, DC: The Jacobs Institute of Women’s Health; 2002.
5.
go back to reference Schootman M, Jeffe DB, Lian M, Aft R, Gillanders WE. Surveillance mammography and the risk of death among elderly breast cancer patients. Breast Cancer Res Treat. 2008;111:489–96.CrossRefPubMed Schootman M, Jeffe DB, Lian M, Aft R, Gillanders WE. Surveillance mammography and the risk of death among elderly breast cancer patients. Breast Cancer Res Treat. 2008;111:489–96.CrossRefPubMed
6.
go back to reference Shapira MM, McAuliffe TL, Nattinger AB. Underutilization of mammography in older breast cancer survivors. Med Care. 2000;38:281–9.CrossRef Shapira MM, McAuliffe TL, Nattinger AB. Underutilization of mammography in older breast cancer survivors. Med Care. 2000;38:281–9.CrossRef
7.
go back to reference Lash TL, Silliman RA. Medical surveillance after breast cancer diagnosis. Med Care. 2001;39:945–55.CrossRefPubMed Lash TL, Silliman RA. Medical surveillance after breast cancer diagnosis. Med Care. 2001;39:945–55.CrossRefPubMed
8.
go back to reference Keating NL, Landrum MB, Guadagnoli E, Winer EP, Ayanian JZ. Factors related to underuse of surveillance mammography. Among breast cancer survivors. J Clin Oncol. 2006;24:85–94.CrossRefPubMed Keating NL, Landrum MB, Guadagnoli E, Winer EP, Ayanian JZ. Factors related to underuse of surveillance mammography. Among breast cancer survivors. J Clin Oncol. 2006;24:85–94.CrossRefPubMed
9.
go back to reference Field TS, Doubeni C, Fox MP, Buist DS, Wei F, Geiger AM, Quinn VP, Lash TL, Prout MN, Yood MU, Frost FJ, Silliman RA. Under utilization of surveillance mammography among older breast cancer survivors. J Gen Intern Med. 2008;23(2):158–63.CrossRefPubMedCentralPubMed Field TS, Doubeni C, Fox MP, Buist DS, Wei F, Geiger AM, Quinn VP, Lash TL, Prout MN, Yood MU, Frost FJ, Silliman RA. Under utilization of surveillance mammography among older breast cancer survivors. J Gen Intern Med. 2008;23(2):158–63.CrossRefPubMedCentralPubMed
10.
go back to reference Fouad M, Wynn T, Martin M, Partridge E. Patient navigation pilot project: results from the community health advisors in action program (CHAAP). Ethn Dis. 2010;20(2):155–61. PubMed Fouad M, Wynn T, Martin M, Partridge E. Patient navigation pilot project: results from the community health advisors in action program (CHAAP). Ethn Dis. 2010;20(2):155–61. PubMed
11.
go back to reference Butler Nattinger A, Schapira MM, Warren JL, Earle CC. Methodological issues in the use of administrative claims data to study surveillance after cancer treatment. Med Care. 2002;40(8 Suppl):IV-69–74. Butler Nattinger A, Schapira MM, Warren JL, Earle CC. Methodological issues in the use of administrative claims data to study surveillance after cancer treatment. Med Care. 2002;40(8 Suppl):IV-69–74.
12.
go back to reference Blustein J. Medicare coverage, supplemental insurance, and the use of mammography by older women. N Engl J Med. 1995;332:1138–43.CrossRefPubMed Blustein J. Medicare coverage, supplemental insurance, and the use of mammography by older women. N Engl J Med. 1995;332:1138–43.CrossRefPubMed
13.
go back to reference May DS, Trontell AE. Mammography use by elderly women: a methodological comparison of two national data sources. Ann Epidemiol. 1998;8(7):439–44.CrossRefPubMed May DS, Trontell AE. Mammography use by elderly women: a methodological comparison of two national data sources. Ann Epidemiol. 1998;8(7):439–44.CrossRefPubMed
14.
go back to reference Randolph WM, Mahnken JD, Goodwin JS, Freeman JL. Using medicare data to estimate the prevalence of breast cancer screening in older women: comparison of different methods to identify screening mammograms. Health Serv Res. 2002;37(6):1643–57.CrossRefPubMedCentralPubMed Randolph WM, Mahnken JD, Goodwin JS, Freeman JL. Using medicare data to estimate the prevalence of breast cancer screening in older women: comparison of different methods to identify screening mammograms. Health Serv Res. 2002;37(6):1643–57.CrossRefPubMedCentralPubMed
15.
go back to reference Randolph WM, Goodwin JS, Mahnken JD, Freeman JL. Regular mammography use is associated with elimination of age-related disparities in size and stage of breast cancer at diagnosis. Ann Intern Med. 2002;137(10):783–90.CrossRefPubMed Randolph WM, Goodwin JS, Mahnken JD, Freeman JL. Regular mammography use is associated with elimination of age-related disparities in size and stage of breast cancer at diagnosis. Ann Intern Med. 2002;137(10):783–90.CrossRefPubMed
16.
go back to reference Cooper GS, Schultz L, Simpkins J, Lafata JE. The utility of administrative data for measuring adherence to cancer surveillance care guidelines. Med Care. 2007;45(1):66–72.CrossRefPubMed Cooper GS, Schultz L, Simpkins J, Lafata JE. The utility of administrative data for measuring adherence to cancer surveillance care guidelines. Med Care. 2007;45(1):66–72.CrossRefPubMed
17.
go back to reference Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002;40:IV-3–18. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002;40:IV-3–18.
18.
go back to reference Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000;53:1258–67.CrossRefPubMed Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000;53:1258–67.CrossRefPubMed
20.
go back to reference Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83.CrossRefPubMed Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83.CrossRefPubMed
21.
go back to reference Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613–9.CrossRefPubMed Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613–9.CrossRefPubMed
22.
go back to reference Warren JL, Harlan LC, Fahey A, et al. Utility of the SEER medicare data to identify chemotherapy use. Med Care. 2002;40(8 Suppl):IV-55–61. Warren JL, Harlan LC, Fahey A, et al. Utility of the SEER medicare data to identify chemotherapy use. Med Care. 2002;40(8 Suppl):IV-55–61.
24.
go back to reference Culler SD, Parchman ML, Przybylski M. Factors related to potentially preventable hospitalizations among the elderly. Med Care. 1998;36(6):804–17.CrossRefPubMed Culler SD, Parchman ML, Przybylski M. Factors related to potentially preventable hospitalizations among the elderly. Med Care. 1998;36(6):804–17.CrossRefPubMed
25.
go back to reference Parchman ML, Culler SD. Preventable hospitalizations in primary care shortage area. An analysis of vulnerable Medicare beneficiaries. Arch Fam Med. 1999;8:487–91.CrossRefPubMed Parchman ML, Culler SD. Preventable hospitalizations in primary care shortage area. An analysis of vulnerable Medicare beneficiaries. Arch Fam Med. 1999;8:487–91.CrossRefPubMed
26.
go back to reference Weissman JS, Gatsonis C, Epstein AM. Rates of avoidable hospitalization by insurance status in Massachusetts and Maryland. JAMA. 1992;268(17):2388–94.CrossRefPubMed Weissman JS, Gatsonis C, Epstein AM. Rates of avoidable hospitalization by insurance status in Massachusetts and Maryland. JAMA. 1992;268(17):2388–94.CrossRefPubMed
27.
go back to reference Earle CC, Burstein HJ, Winer EP, Weeks JC. Quality of non-breast cancer health maintenance among elderly breast cancer survivors. J Clin Oncol. 2003;21(8):1447–51.CrossRefPubMed Earle CC, Burstein HJ, Winer EP, Weeks JC. Quality of non-breast cancer health maintenance among elderly breast cancer survivors. J Clin Oncol. 2003;21(8):1447–51.CrossRefPubMed
28.
go back to reference Rao S, Kubisiak J, Gilden D. Cost of illness associated with metastatic breast cancer. Breast Cancer Res Treat. 2004;83(1):25–32.CrossRefPubMed Rao S, Kubisiak J, Gilden D. Cost of illness associated with metastatic breast cancer. Breast Cancer Res Treat. 2004;83(1):25–32.CrossRefPubMed
29.
30.
go back to reference Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med. 1997;127(8 Pt 2):757–63.CrossRefPubMed Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med. 1997;127(8 Pt 2):757–63.CrossRefPubMed
31.
go back to reference Brookhart MA, Schneeweiss S, Rothman KJ, Glynn RJ, Avorn J, Sturmer T. Variable selection for propensity score models. Am J Epidemiol. 2006;163(12):1149–56.CrossRefPubMedCentralPubMed Brookhart MA, Schneeweiss S, Rothman KJ, Glynn RJ, Avorn J, Sturmer T. Variable selection for propensity score models. Am J Epidemiol. 2006;163(12):1149–56.CrossRefPubMedCentralPubMed
32.
go back to reference Weitzen S, Lapane KL, Toledano AY, Hume AL, Mor V. Principles for modeling propensity scores in medical research: a systematic literature review. Pharmacoepidemiol Drug Saf. 2004;13:841–53.CrossRefPubMed Weitzen S, Lapane KL, Toledano AY, Hume AL, Mor V. Principles for modeling propensity scores in medical research: a systematic literature review. Pharmacoepidemiol Drug Saf. 2004;13:841–53.CrossRefPubMed
33.
go back to reference Robert O. Morgan, Virnig BA, Petersen LA et al. Medicare + Choice and Minority Elderly Final report for R01AG019284-03, May 31, 2009. Robert O. Morgan, Virnig BA, Petersen LA et al. Medicare + Choice and Minority Elderly Final report for R01AG019284-03, May 31, 2009.
34.
go back to reference Paszat L, Sutradhar R, Grunfeld E, Gainford C, Benk V, Bondy S, Coyle D, Holloway C, Sawka C, Shumak R, Vallis K, van Walraven C. Outcomes of surveillance mammography after treatment of primary breast cancer: a population-based case series. Breast Cancer Res Treat. 2009;114(1):169–78.CrossRefPubMed Paszat L, Sutradhar R, Grunfeld E, Gainford C, Benk V, Bondy S, Coyle D, Holloway C, Sawka C, Shumak R, Vallis K, van Walraven C. Outcomes of surveillance mammography after treatment of primary breast cancer: a population-based case series. Breast Cancer Res Treat. 2009;114(1):169–78.CrossRefPubMed
35.
go back to reference Brown ML, Houn F, Sickles EA, Kessler LG. Screening mammography in community practice: positive predictive value of abnormal findings and yield of follow-up diagnostic procedures. AJR Am J Roentgenol. 1995;165(6):1373–7.CrossRefPubMed Brown ML, Houn F, Sickles EA, Kessler LG. Screening mammography in community practice: positive predictive value of abnormal findings and yield of follow-up diagnostic procedures. AJR Am J Roentgenol. 1995;165(6):1373–7.CrossRefPubMed
36.
go back to reference Lairson DR, Chan W, Chang YC, Del Junco DJ, Vernon SW. Cost-effectiveness of targeted versus tailored interventions to promote mammography screening among women military veterans in the United States. Eval Program Plan. 2011;34(2):97–104.CrossRef Lairson DR, Chan W, Chang YC, Del Junco DJ, Vernon SW. Cost-effectiveness of targeted versus tailored interventions to promote mammography screening among women military veterans in the United States. Eval Program Plan. 2011;34(2):97–104.CrossRef
37.
38.
go back to reference Freeman HP, Rodriguez RL. History and principles of patient navigation. Cancer. 2011;117(15 suppl):3539–42.PubMed Freeman HP, Rodriguez RL. History and principles of patient navigation. Cancer. 2011;117(15 suppl):3539–42.PubMed
39.
Metadata
Title
Surveillance mammography use after treatment of primary breast cancer and racial disparities in survival
Authors
Z. Z. Nurgalieva
L. Franzini
R. Morgan
S. W. Vernon
C. C. Liu
X. L. Du
Publication date
01-12-2013
Publisher
Springer US
Published in
Medical Oncology / Issue 4/2013
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-013-0691-8

Other articles of this Issue 4/2013

Medical Oncology 4/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine